معرفی
Mart Roosimaa is a physician scientist with a focus on endocrinology, bioenergetics, and metabolic disorders. He has held clinical and academic positions at the University of Tartu, Faculty of Medicine, including roles as Assistant in Pathophysiology and PhD candidate. Currently, he serves as a Medical Science Liaison at Nanordica Medical OÜ (since 2023), and has held leadership roles such as Chief Executive Officer at Keila Haigla (2022–2023) and Chief of Endocrinology at North Estonia Medical Centre (2019–2022).
His academic training includes interrupted PhD studies in medicine (2011–2017) at the University of Tartu, centered on "Interactomic approach for evaluating energy metabolism in different pathophysiological states". His research spans translational medicine, mitochondrial function, and age-related muscle weakness, with publications on diabetes management, cardiac metabolism, and skeletal muscle pathophysiology.
Mart has contributed to national clinical guidelines for type 2 diabetes and chronic kidney disease, and serves in advisory roles for the Estonian Endocrine Society and Ministry of Social Affairs. His scholarly work includes 33 publications, with recent articles on GLP-1 receptor agonists, hexokinase overexpression, and mitochondrial bioenergetics.
